GlobeNewswire

Reflect Scientific Announces Liquid Nitrogen Cooling Technology for AI Data Center Applications
15/09/2026
OREM, Utah, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), today announced that its proprietary liquid nitrogen temperature control technology is available for application in the rapidly [...]
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
15/09/2026
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search process BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation ( [...]
Egle Therapeutics to Present Clinical Data at the Upcoming European Academy of Dermatology and Venereology (EADV) Congress in Vienna
15/09/2026
Egle to share clinical data on EGL-003, the company's most advanced Treg-selective IL-2 agonist for atopic dermatitis PARIS, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics (“Egle”), a clinical-stage biotechnology [...]
Art Meets Whiskey: Breckenridge Distillery Debuts Limited-Edition Collectors Series Release with Pat Milbery
15/09/2026
Limited-Edition Release Continues Distillery's Celebration of the Art of Blending Through Whiskey, Visual Art and Community BRECKENRIDGE, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery , one of the [...]
VitalHub Announces Expansion of AI Capabilities with Launch of AI Scribe
15/09/2026
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today the launch of VitalHub AI Scribe, an ambient clinical intelligence (“ACI”) solution that [...]
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
15/09/2026
– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day 7 compared to [...]
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
15/09/2026
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission [...]
Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency
15/09/2026
- Daphne Karydas appointed as President and Chief Financial Officer - Weston Miller, MD, appointed as Chief Medical Officer - Additional appointments: Nina Hunter, PhD, as Chief Development Officer and Shiva G. Fritsch [...]
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
15/09/2026
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease [...]
Walden Biosciences Announces CMO Appointment and Upcoming Clinical Data for WAL0921 in Proteinuric Chronic Kidney Disease
15/09/2026
Rekha Abichandani, M.D., appointed Chief Medical Officer Enrollment nearing completion in Phase 2 basket study of WAL0921; initial data from diabetic kidney disease cohorts to be presented in fourth quarter 2026 Data [...]
The Waqf Fund acquires UK retail property to fund charitable work for generations to come
15/09/2026
MANCHESTER, United Kingdom, Sept. 15, 2026 (GLOBE NEWSWIRE) -- The Waqf Fund announced a key real estate acquisition as a charity endowment. The fund has completed the £1.9 million purchase of a prime freehold retail [...]
Profusa, Inc. Receives Nasdaq Compliance Determination
15/09/2026
Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced today that on September 9, 2026, the Company received a letter (the “Compliance Determination Letter”) from The [...]
Hummingbird Bioscience Appoints Dr. James Garner as President
15/09/2026
Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience (“ [...]
TOLREMO therapeutics Completes Phase I Study of TT125-80 and Presents Final Clinical Data at World Conference on Lung Cancer 2026
15/09/2026
Final Phase 1 data provide clinical validation of CBP/p300 as a novel therapeutic target for overcoming transcriptional resistance in NSCLC TT125-802 demonstrates monotherapy anti-tumor activity across biologically [...]
Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program
15/09/2026
Financing co-led by Heal Capital and Ananda Impact Ventures will advance the Aitios® platform and ongoing validation of lead program to identify preeclampsia risk in a pregnancy’s first trimester Dr. Gordon Sanghera CBE [...]
Orvida Pharma Announces Interim Financing Led by Recordati to Advance Ontivatrep Development for Rare Genetic Skin Diseases
15/09/2026
Proceeds to support continued clinical development of ontivatrep, an oral TRPV3 inhibitor, with Phase 1b topline results in Olmsted syndrome expected by the end of 2026 NESS ZIONA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE [...]
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
15/09/2026
Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise Bezisterim showed a [...]
Avicanna to Present at a Life Sciences Investor Forum on September 17, 2026
15/09/2026
TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that [...]
Ontario Healthcare Stakeholders Unite on Shared Action Plan to Reduce Tobacco and Nicotine Dependence
15/09/2026
Vanguard healthcare, policy, and community stakeholders consolidate as newly formed Ontario Nicotine Action Table (ONAT) to build long-term plan for coordinated action TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- A broad [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum